Search research articles
Contact Us
Filters
Showing results (101-110 of 114) with videos related to
Page
of 12
Sort By:
The EMBO Journal
|
October 31, 2025
Auto-inhibition of PRC2 by the broadly expressed long isoform of AEBP2
Marlena Mucha, Zhihao Lai, Nicholas J McKenzie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2026
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)
N Frost, M Joosten, J Franzen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
P D Bonomi, D Gandara, F R Hirsch, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial
R A Soo, K Vervita, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
S Peters, J-L Pujol, U Dafni, et al.
ESMO Open
|
February 13, 2024
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial
S Michels, B Massutí, I Vasyliv, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 9, 2022
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
M Janning, J Süptitz, C Albers-Leischner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 24, 2020
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts
P M Putora, G F Fischer, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 28, 2022
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]
S Novello, V Torri, C Grohe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer
S Novello, V Torri, C Grohe, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 114) with videos related to
Sort By:
Page
of 12
The EMBO Journal
|
October 31, 2025
Auto-inhibition of PRC2 by the broadly expressed long isoform of AEBP2
Marlena Mucha, Zhihao Lai, Nicholas J McKenzie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2026
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)
N Frost, M Joosten, J Franzen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
P D Bonomi, D Gandara, F R Hirsch, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 2025
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial
R A Soo, K Vervita, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
S Peters, J-L Pujol, U Dafni, et al.
ESMO Open
|
February 13, 2024
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial
S Michels, B Massutí, I Vasyliv, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 9, 2022
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
M Janning, J Süptitz, C Albers-Leischner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 24, 2020
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts
P M Putora, G F Fischer, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 28, 2022
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]
S Novello, V Torri, C Grohe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer
S Novello, V Torri, C Grohe, et al.
Page
of 12